Table 1 Baseline demographics and clinical characteristics (2014 cohort)
From: Evaluation of exacerbations and blood eosinophils in UK and US COPD populations
Characteristic | CPRD database N = 15,364 | Optum database N = 139,465 |
|---|---|---|
Age, years, mean (SD) | 71.8 (10.4) | 71.8 (10.6) |
Gender | ||
Men | 8,383 (54.6%) | 71,417 (51.2%) |
Women | 6,981 (45.4%) | 68,047 (48.8%) |
Charlson Comorbidity Indexa, median (IQR) | 2.0 (1.0–4.0) | 2.0 (0.0–3.0) |
Baseline comorbidities common to COPD patientsb | ||
Hypertension | 9,133 (59.4%) | 106,687 (76.5%) |
Hyperlipidaemia | 5,972 (38.9%) | 91,779 (65.8%) |
Depression | 5,321 (34.6%) | 26,030 (18.7%) |
Anxiety | 4,524 (29.4%) | 23,138 (16.6%) |
Cancer | 3,915 (25.5%) | 32,729 (23.5%) |
Diabetes | 2,755 (17.9%) | 46,588 (33.4%) |
Baseline medicationsc | ||
ICS | 1,078 (7.0%) | 5,900 (4.2%) |
LABA | 513 (3.3%) | 1,556 (1.1%) |
LAMA | 3,658 (23.8%) | 24,850 (17.8%) |
LAMA + LABA | 423 (2.8%) | 615 (0.4%) |
ICS + LABA | 4,938 (32.1%) | 29,763 (21.3%) |
ICS + LAMA + LABA | 5,563 (36.2%) | 10,490 (7.5%) |
Smoking status | ||
Patients with smoking data reported, n | 15,356 | – |
Current smokers | 4,996 (32.5%) | – |
Ex-smokers | 9,499 (61.8%) | – |
Non-smokers | 861 (5.6%) | – |
GOLD classificationd | ||
Patients with GOLD assessment, n | 6,029 | – |
Group A | 449 (7.4%) | – |
Group B | 1,843 (30.6%) | – |
Group C | 309 (5.1%) | – |
Group D | 3,428 (56.9%) | – |
mMRC dyspnoea scale | ||
Patients with mMRC data, n | 10,899 | – |
Grade 0 | 1,341 (12.3%) | – |
Grade 1 | 3,941 (36.2%) | – |
Grade 2 | 3,157 (29.0%) | – |
Grade 3 | 2,033 (18.7%) | – |
Grade 4 | 427 (3.9%) | – |
Patients with FEV1 % predicted data | 7,331 (47.7%) | – |
FEV1, % predicted, mean (SD) | 61.6 (21.6) | – |
Patients with FEV1/FVC data | 6,769 (44.1%) | – |
FEV1/FVC, %, mean (SD) | 60.2 (16.0) | – |